GHRP-6
Growth Hormone Releasing Peptide-6
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that potently stimulates growth hormone release by acting as a ghrelin mimetic at the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary gland. It was one of the first synthetic GH secretagogues developed and is notable for producing robust GH pulses along with significant appetite stimulation through ghrelin pathway activation. Research applications include GH deficiency assessment, muscle wasting conditions, and studies of appetite regulation and metabolic function.
Mechanism of Action
First-generation synthetic hexapeptide GHSR agonist. Potent ghrelin mimetic that stimulates GH release and strongly increases appetite. Also activates the vagus nerve, promoting gastroprotective effects and gastric motility. Less selective than ipamorelin or GHRP-2.
Research Protocols
For research purposes only. Not medical advice.
Research protocols use 100-300mcg 2-3 times daily via subcutaneous injection on an empty stomach. Expect significant hunger increase within 20 minutes of injection. Often combined with CJC-1295 no DAC.
Research Notes
Clinical Research Status
GHRP-6 has been extensively studied in clinical research settings since the early 1990s as both a diagnostic tool for GH deficiency and a potential therapeutic agent for catabolic conditions. It has been used in over 100 published clinical studies as a GH provocation test, often combined with GHRH for maximal diagnostic sensitivity. While widely available through compounding pharmacies and research suppliers, GHRP-6 has not received FDA approval for any therapeutic indication, though it remains an important research tool in endocrinology.
Key Published Findings
Clinical studies demonstrate that GHRP-6 produces dose-dependent GH release with peak plasma levels occurring 15-30 minutes after subcutaneous administration, with typical GH elevations of 5-15 fold above baseline. Research has confirmed that GHRP-6 stimulates GH release through a mechanism complementary and synergistic with GHRH, producing greater combined GH output than either peptide alone. Studies in elderly subjects show preserved GHRP-6 responsiveness compared to the age-related decline in GHRH efficacy, suggesting the ghrelin pathway remains functional in aging.
Safety Profile
GHRP-6 is well-tolerated in clinical studies with transient side effects including facial flushing, mild dizziness, and intense hunger occurring shortly after administration. Cortisol and prolactin elevations are modest and transient compared to the robust GH response. Chronic administration studies have not revealed significant safety concerns, though long-term data beyond 6-12 months of continuous use is limited in human subjects.
Drug Interactions & Contraindications
GHRP-6 may potentiate the effects of exogenous GH or GHRH when administered concurrently, requiring dose adjustments in individuals already on GH therapy. The significant appetite stimulation may counteract the effects of appetite suppressants or medications for weight management. Patients with diabetes should monitor blood glucose carefully, as acute GH release can transiently impair insulin sensitivity, and the appetite stimulation may affect glycemic control.
Comparison to Related Compounds
GHRP-6 produces notably stronger appetite stimulation than GHRP-2, Ipamorelin, or Hexarelin due to its high affinity for the ghrelin receptor and downstream activation of hunger signaling. Ipamorelin is often preferred for users who want GH release without appetite increase, as it is more selective for GH secretion with minimal effect on cortisol, prolactin, or appetite. Hexarelin produces the strongest absolute GH release of the GHRP family but undergoes rapid desensitization, while GHRP-6 maintains efficacy with repeated dosing.
Community Observations
Users consistently report intense hunger onset within 20-30 minutes of GHRP-6 injection, making it popular among those seeking to increase caloric intake for muscle gain but problematic for those pursuing fat loss. Typical dosing ranges from 100-300mcg subcutaneously 2-3 times daily, often administered 30 minutes before meals to capitalize on the appetite stimulation. The community frequently uses GHRP-6 in combination with Mod GRF 1-29 (CJC-1295 no DAC) to synergistically amplify GH output, with users reporting improved sleep quality, faster recovery, and gradual improvements in body composition over 3-6 months.
Half-Life
~1-2 hours
Reconstitution
Bacteriostatic water (BAC)
Storage
Lyophilized
Refrigerate 2-8C up to 18 months.
Reconstituted
Refrigerate 2-8C. Use within 14 days.
US Legal Status
Also Known As
PeptideVault provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.
Read full disclaimer